R

Rainier Clinical Research Center | Renton, WA

Research site
(Unclaimed)
Location
800 SW 39th Street Suite 110, Renton, Washington, United States of America
Site insights

Top conditions

Diabetes Mellitus (46 trials)

Type 2 Diabetes Mellitus (34 trials)

Type 1 Diabetes Mellitus (24 trials)

Obesity (9 trials)

Diabetic Neuropathies (8 trials)

Top treatments

LY3556050
Tirzepatide
LY3298176
LY3526318
LY3437943
LY3857210
Glucose
AC2993
LY3209590
LY3016859

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

22 of 110
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain (CPMP)

The purpose of the chronic pain master protocol is to compare independent pain interventions and establish an overarching structure for the disease-s...

Enrolling
Chronic Low-back Pain
Diabetic Neuropathic Pain
Drug: LY3526318 ISA
Drug: LY3857210 ISA

This is a 2-part, randomized, placebo-controlled, double-blind, Phase 2 study to evaluate the safety, tolerability, efficacy, and PK of RTA 901 in qu...

Enrolling
Diabetic Peripheral Neuropathic Pain
Drug: Placebo
Drug: RTA 901

A randomized controlled trial (RCT) to assess the safety and efficacy of use of Control-IQ technology in adults with type 2 diabetes using basal-bolu...

Enrolling
Type 2 Diabetes Treated With Insulin
Device: t:slim X2 insulin pump with Control-IQ technology 1.5 and Dexcom G6 CGM
Device: Standard Therapy plus continuous glucose monitoring (CGM)
Locations recently updated

The main purpose of this study is to measure the safety and efficacy of insulin efsitora alfa (LY3209590) compared with insulin degludec in participa...

Active, not recruiting
Diabetes
Type 1 Diabetes
Drug: Insulin Degludec
Drug: Insulin Efsitora Alfa

The reason for this study is to see if the study drug insulin efsitora alfa (LY3209590) is safe and effective in participants with Type 2 diabetes th...

Active, not recruiting
Type 2 Diabetes
Drug: Insulin Efsitora Alfa
Drug: Insulin Degludec
Locations recently updated

The main purpose of this study is to determine the safety and efficacy of LY3556050 versus placebo in participants with diabetic peripheral neuropath...

Enrolling
Diabetic Peripheral Neuropathy
Drug: Placebo
Drug: LY3556050

The main purpose of this study is to assess efficacy and safety of orforglipron compared with oral semaglutide in participants with Type 2 diabetes a...

Enrolling
Type 2 Diabetes
Drug: Orforglipron
Drug: Semaglutide
Locations recently updated

The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master pr...

Enrolling
Overweight
Knee Pain Chronic
Drug: Retatrutide
Drug: Placebo
Locations recently updated

The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiov...

Enrolling
Obesity
Cardiovascular Diseases
Drug: Placebo
Drug: Retatrutide

This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additiona...

Active, not recruiting
Overweight
Obesity
Drug: Placebo
Drug: Tirzepatide

The main purpose of this study is to evaluate the efficacy of mRNA 1647 vaccine in CMV-seronegative female participants and to evaluate the safety an...

Active, not recruiting
Cytomegalovirus Infection
Biological: mRNA-1647
Biological: Placebo

The main purpose of Part A of this study is to evaluate the safety and tolerability of mRNA-1345 vaccine and to demonstrate the efficacy of a single...

Active, not recruiting
Respiratory Syncytial Virus
Drug: mRNA-1345
Drug: Placebo

This study is open to adults who are at least 18 years old and have a body mass index of 27 kg/m² or more. People can take part if they have type 2 d...

Enrolling
Obesity
Diabetes Mellitus, Type 2
Drug: Survodutide
Drug: Placebo
Status recently updated

This study is open to adults who are at least 18 years old and havea body mass index (BMI) of 30 kg/m² or more, ora BMI of 27 kg/m² or more and at le...

Enrolling
Active, not recruiting
Obesity
Drug: Placebo
Drug: survodutide

This is a single center, single arm non-randomized study of 48-hour CGMIS wear duration incorporating two meal-challenge tests to explore the perform...

Enrolling
Type1diabetes
Device: CGMIS (Continuous Glucose Monitoring Infusion Set)

A Prospective, Multicenter Evaluation of Accuracy and Safety of the Eversense CGM System with Enhanced Features. The purpose of this clinical investi...

Enrolling
Diabetes Mellitus, Type 1
Diabetes Mellitus
Device: Continuous Glucose Monitoring System

This global study (US, Canada, and Australia) will evaluate the safety and effectiveness of the MiniMed 780G system in type 1 adult and pediatric sub...

Active, not recruiting
Type 1 Diabetes
Device: MiniMed 780G System

The objective of the study is to assess the safety and effectiveness of MiniMed™ 780G system in adult subjects with insulin-requiring type 2 diabetes...

Enrolling
Type 2 Diabetes Treated With Insulin
Device: MiniMed™ 780G Insulin Pump system

The purpose of this study is to collect clinical data to support a 7-day wear of the Extended Wear Infusion Set (EWIS).Participants will be asked to:...

Enrolling
Type1diabetes
Device: SteadiSet Extended Wear Infusion Set

The purpose of this study is to evaluate the effect and safety of tirzepatide in participants with obstructive sleep apnea and obesity who are both u...

Active, not recruiting
Obesity
Sleep Apnea
Drug: Tirzepatide
Drug: Placebo

Trial sponsors

Lilly logo

Lilly (40 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems